In a review of the first quarter, the Roche Group has highlighted the progress of the checkpoint antibody atezolizumab, which is being investigated in both solid and haematologic cancers, and ocrelizumab, a new drug for multiple sclerosis. ---Subscribe to MedNous to access this article--- Company News
